Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Marinus Pharmaceuticals

< Previous 1 2 3 4 Next >
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 ZTALMY® Net Product Revenue and Provides Business Update
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Proposed Public Offering
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces $32.5 Million Revenue Interest Financing Agreement with Sagard Healthcare Partners
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 8, 2022
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 11, 2022
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS